Accueil   Diary - News   All news Biom’up and Athyrium close first tranche of bond financing for €25 million with stock warrants attached

Biom’up and Athyrium close first tranche of bond financing for €25 million with stock warrants attached

 

 

Saint-Priest, France, April 3, 2018 – 7.15 am Paris time – Biom’up (the “Company”), a specialist in surgical hemostasis, announced today the successful issuance by way of private placement of a €25 million bond with stock warrants attached subscribed by Athyrium Opportunities III Acquisition LP, a fund managed by Athyrium Capital Management, L.P. ("Athyrium"), as initially announced on February 14, 2018. This brings the total amount raised post-IPO to €41 million (€16 million in equity plus €25 million from the bond issue). Subject to certain conditions the bond issue may be topped up by an additional €10 million within a year.

 



The net proceeds from the recent equity raise and the bond issue will be used to increase Biom’up’s existing production capacity of HEMOBLASTTM Bellows, support the mid-2018 commercial rollout of HEMOBLAST Bellows in Europe and the U.S., add a second manufacturing facility close to the existing unit in Saint‑Priest, fund further preclinical and clinical trials for HEMOBLAST Bellows and HEMOSNOWTM and, finally, repay €7.6 million of the venture loan from Kreos Capital V (UK) Limited (“Kreos”).).

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree